Dara BioSciences goes public in reverse merger
Dara BioSciences has completed a reverse merger with the nearly-defunct Point Therapeutics, taking the company public. In the deal Dara technically became a subsidiary of Point as a preliminary move to changing the combined company's name to Dara BioSciences. Point Therapeutics jettisoned its executive staff and all but two full-time employees after it shuttered a late-stage trial of talabostat for non-small cell lung cancer. Dara's shareholders control 96.4 percent of the combined company's stock.
- see this release
- read the report from MassHighTech
Related Articles:
DARA owners acquire troubled Point Therapeutics. Report
Dara licenses Bayer drugs. Report
More cuts at troubled Point Therapeutics. Report
Be the first to comment
More stories about pharmaceuticals Drug Trials combined company shareholders Bayer Schering lung cancer Talabostat
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
